The Economics of Personalized Medicine | GenomeWeb

The Wall Street Journal's Hester Plumridge writes that personalized medicine offers advantages, but also poses challenges for pharmaceutical companies. Giving patients a drug that is known to be effective for their genetic profile not only will lower health care costs and limit adverse reactions, but also, Plumridge says, minimize the number of liability claims filed against pharma companies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.